ALINITY m HR HPV ASSAY

ALINITY m HR HPV ASSAY image
ALINITY m HR HPV ASSAY image
ALINITY m HR HPV ASSAY image

Alinity m high risk HPV assay delivers timely and clinically relevant information on 14 high risk HPV genotypes which combined with uniquely matched outstanding workflow efficiency while meeting the needs of the clinicians and laboratories.

• Integrated evidence based risk stratification by separately reporting HPV genotypes 16, 18, 45 and two pools of HR HPV genotypes in ONE single reaction

• Multiplex detection of 14 high risk genotypes for the general and vaccinated population by enabling clinical practice for the future through next level risk stratification

• Built in cellular control provides diagnostic confidence in negative results by ensuring sample adequacy, which in turn helps guide patient management.

The Alinity m High Risk (HR) HPV assay is a qualitative in vitro test for use with the automated Alinity m System for the detection of DNA from 14 high-risk human papillomavirus (HPV) genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 in clinical specimens. The assay specifically identifies HPV genotypes 16, 18, and 45 while reporting the concurrent detection of the other high-risk genotypes (31/ 33/ 52/ 58) and (35/ 39/ 51/ 56/ 59/ 66/ 68) at clinically relevant infection levels. The Alinity m HR HPV assay is intended for the following uses: 

  • To screen patients with ASC-US (atypical squamous cells of undetermined significance) cervical cytology test results to determine the need for referral to colposcopy. The results of this test are not intended to prevent women from proceeding to colposcopy.
  • To be used with cervical cytology to adjunctively screen to assess the presence or absence of high-risk HPV genotype.
  • To be used as a first-line primary screening test to identify women at increased risk for the development of cervical cancer or the presence of high-grade disease.
  • To assess the presence or absence of HPV genotypes 16 and 18 to identify women at increased risk for the development of cervical cancer or the presence of high-grade disease with or without cervical cytology.

The results from the Alinity m HR HPV, together with the physician’s assessment of cytology, history, other risk factors, and professional guidelines, may be used to guide patient management.

 

ALINITY m HR HPV ASSAY PERFORMANCE
Target Region

 

L1 Region

Limit of Detection (LoD) The LOD was defined as a concentration having a ≥95% detection rate with all higher concentrations having a ≥95% detection rate.
Carryover 0.0%
External Control Positive Control, Negative Control
Cellular Control Detects the endogenous human beta globin, (BG) sequence as Cellular Control (CC) signal to evaluate cell adequacy, sample extraction and amplification efficiency
Collection Device Alinity m cervi-collect specimen collection kit
Sample Input Volume

 

400 μL

Specimen Types

Cervical specimen collected in Alinity m Cervi-Collect Specimen Collection

Cervical specimen collected in ThinPrep PreservCyt Solution and SurePath Preservative Fluid